HomeCompareIFMK vs PFE

IFMK vs PFE: Dividend Comparison 2026

IFMK yields 400000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IFMK wins by $5.011119029548644e+32M in total portfolio value
10 years
IFMK
IFMK
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full IFMK calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — IFMK vs PFE

📍 IFMK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIFMKPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IFMK + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IFMK pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IFMK
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, IFMK beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IFMK + PFE for your $10,000?

IFMK: 50%PFE: 50%
100% PFE50/50100% IFMK
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

IFMK
No analyst data
Altman Z
0.3
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IFMK buys
0
PFE buys
0
No recent congressional trades found for IFMK or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIFMKPFE
Forward yield400000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$5.011119029548644e+32M$49.6K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$26,258.71
Total dividends collected$5.010957816668433e+32M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IFMK vs PFE ($10,000, DRIP)

YearIFMK PortfolioIFMK Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$40,010,700$40,000,000.00$9,153$693.39+$40.00MIFMK
2$149,615,521,729$149,572,710,280.37$8,593$849.25+$149615.51MIFMK
3$522,880,052,725,200$522,719,964,116,949.25$8,336$1,066.78+$522880052.72MIFMK
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$8,437$1,384.80+$1707862989289.04MIFMK
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$9,013$1,875.40+$5213509402845684.00MIFMK
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$10,306$2,680.72+$14874219058409543680.00MIFMK
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$12,820$4,101.38+$3.966119623405075e+22MIFMK
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$17,673$6,826.70+$9.88384363503273e+25MIFMK
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$27,543$12,591.86+$2.302052364743449e+29MIFMK
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$49,560$26,258.71+$5.011119029548644e+32MIFMK

IFMK vs PFE: Complete Analysis 2026

IFMKStock

iFresh Inc., through its subsidiaries, operates a network of grocery supermarket chains in the north-eastern United States. It operates through Wholesale and Retail segments. The company provides vegetables, seafood, meat, fruits, snacks, seasonings, and spices, such as peanut oil, cooking wine, vinegar, dark soy sauce, black bean sauce, pepper oil, and chilly oil; tea, condiments, canned goods, flour products, marine food products, candies groceries, traditional Chinese medicine, health products, and dried food; rice and rice products; assortment of noodles, frozen vegetables, frozen dumplings, frozen seafood products, and aquatic products; and cooking utensils. Its brand portfolio includes Family Elephant, Feiyan, Green Acre, Golden Smell, Redolent, and I FRESH. The company also distributes its products to wholesale stores, retail supermarkets, and restaurants. As of August 10, 2020, it operated nine retail supermarkets and two in-house wholesale businesses. The company offers its products through online sales channels and delivery network in suburban areas. iFresh Inc. was founded in 1995 and is headquartered in Long Island City, New York.

Full IFMK Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this IFMK vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IFMK vs SCHDIFMK vs JEPIIFMK vs OIFMK vs KOIFMK vs MAINIFMK vs JNJIFMK vs MRKIFMK vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.